Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
California
-
Concord, California, Forenede Stater, 94520
- East Bay Clinical Trial Ctr
-
Long Beach, California, Forenede Stater, 90803
- Ocean View Internal Medicine
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32801
- Florida ID Group
-
Tampa, Florida, Forenede Stater, 33617
- Clinical Pharmacology Services
-
Tampa, Florida, Forenede Stater, 33602
- Hillsborough County Health Dept
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60064
- Veterans Affairs Med Ctr of North Chicago
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 661607415
- Univ of Kansas Med Ctr
-
-
New Jersey
-
Newark, New Jersey, Forenede Stater, 07102
- Saint Michael's Med Ctr
-
Newark, New Jersey, Forenede Stater, 071032757
- UMDNJ - New Jersey Med School
-
-
New York
-
Bronx, New York, Forenede Stater, 10461
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
-
Brooklyn, New York, Forenede Stater, 112123198
- Brookdale Univ Hosp and Med Ctr
-
Brooklyn, New York, Forenede Stater, 11201
- Addiction Research and Treatment Corp
-
New York, New York, Forenede Stater, 10029
- Mount Sinai School of Medicine
-
New York, New York, Forenede Stater, 10011
- Howard Grossman
-
New York, New York, Forenede Stater, 10011
- Gervais Frechette
-
Rochester, New York, Forenede Stater, 14642
- Univ of Rochester Med Ctr
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28211
- SMO-USA Inc
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Advanced Clinical Trials Inc
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson Univ
-
-
Texas
-
Galveston, Texas, Forenede Stater, 775550835
- Univ of Texas Med Branch
-
Houston, Texas, Forenede Stater, 77054
- MacGregor Med Association
-
Irving, Texas, Forenede Stater, 75038
- Walter Gaman
-
San Antonio, Texas, Forenede Stater, 78229
- Southwest Texas Methodist Hosp
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Patients may be eligible for this study if they:
- Are at least 13 years old (consent of parent or guardian required if under 18).
- Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children.
- Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRT) or protease inhibitor (PI).
- Have a viral load (amount of HIV in the blood) of 5,000 copies/ml or more, or have a positive result at the screening visit.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Abuse drugs or alcohol in a way that would interfere with the study, in the opinion of the doctor. Patients stable on methadone will be considered for participation.
- Have an active/acute CDC Category C event.
- Are unable to absorb or take medicines by mouth.
- Are pregnant or breast-feeding.
- Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient.
- Have had pancreatitis or hepatitis within the last 6 months.
- Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study.
- Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken.
- Have received HIV vaccine within 3 months before the study drug will be taken.
- Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study.
- Have received experimental treatments.
- Have allergies which might interfere with the study, in the opinion of the doctor.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Interventionel model: Parallel tildeling
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Proteasehæmmere
- HIV-proteasehæmmere
- Virale proteasehæmmere
- Lamivudin
- Nelfinavir
- Abacavir
- Fosamprenavir
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 316A
- APV30001
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .